Back to Clinical Trials

Brief Title: Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma

A Phase 2 Study Evaluating Futibatinib (TAS 120) Plus Pembrolizumab in the Treatment of Advanced or Metastatic Urothelial Carcinoma

INTRODUCTION

  • Org Study ID: TAS-120-203
  • Secondary ID: N/A
  • NTC ID: NCT04601857
  • Sponsor: Taiho Oncology, Inc.

BRIEF SUMMARY

The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or metastatic urothelial cancer who are not candidates to receive a platinum-based treatment regimens.

  • Overall Status
    Recruiting
  • Start Date
    January 21, 2021
  • Phase
    Phase 2
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Objective response rate (ORR)

Primary Outcome 1 - Timeframe: Approximately 12 months

CONDITION

  • Advanced and Metastatic Urothelial Cancer

ELIGIBILITY

Inclusion Criteria:
Willing and able to provide written informed consent for the trial.

- Age ≥ 18 years of age
Histologically confirmed advanced or metastatic urothelial carcinoma who have not received systemic treatment for advanced metastatic disease.
Cohort A: must have an FGFR3 mutation or FGFR1-4 fusion/rearrangement.

- Cohort B: all other patients with UC (including patients with other FGFR or non-FGFR genetic aberrations and patients with wild-type [non-mutated] tumors)

- Unfit for or intolerant to standard platinum-based chemotherapy.

- Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1.

- Adequate organ function.

- Have a measurable disease per RECIST 1.1
Exclusion Criteria:
Have received prior therapy with anti-PD-1, anti-PD-L1/L2 agent or FGFR inhibitor.
History and/or current evidence of any of the following disorders:
Non-tumor related alteration of the calcium-phosphorus homeostasis that is considered clinically significant in the opinion of the Investigator.

- Ectopic mineralization/calcification considered clinically significant in the opinion of the Investigator.

- Retinal or corneal disorder considered clinically significant in the opinion of the Investigator.

- Has received major surgery within the previous 4 weeks.

- Has received any non-investigational anticancer therapy within the previous 3 weeks (mitomycin within the previous 5 weeks).

- Is currently participating in a study of an investigational agent/device, or has participated in a study of an investigational agent or used an investigational device within 4 weeks prior to the first dose of study treatment.

- Has received a live vaccine within 30 days prior to the first dose of study drug.

- Have an active autoimmune disease that has required systemic treatment in the past 2 years.

- Have a history of (noninfectious) pneumonitis that required steroids or has current pneumonitis.

- Have had an allogenic tissue/ organ transplant.

- Has known human immunodeficiency virus (HIV) and/or history of Hepatitis B or C infections, or known to be positive for Hepatitis B antigen (HBsAg)/ Hepatitis B virus (HBV) DNA or Hepatitis C Antibody or RNA.

- Have known active central nervous system metastases and/or carcinomatous meningitis.

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.

- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: N/A

Role: N/A

Affiliation: N/A

Overall Contact

Name: N/A

Phone: 1-609-250-7336

Email: clinicaltrialinfo@taihooncology.com

LOCATION

Facility Status Contact
Facility: Henry Ford Hospital
Detroit, Michigan 48202
United States
Status: Recruiting Contact: Contact
Clara Hwang